EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping ReviewOpen Access · CC BY 4.0

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies—A Scoping Review

Lambros Athanassiou, Ifigenia Kostoglou-Athanassiou iD, Georgia Kaiafa, Christos Savopoulos, Yehuda Shoenfeld, Panagiotis Athanassiou iD

Life · 29.04.2026 · 16 (5) · 740

DOI: 10.3390/life16050740 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 29.04.2026. Verfasst von Lambros Athanassiou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, St. Paul's Hospital, 55134 Thessaloniki, Greece. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriatic arthritis (PsA) is a systemic autoimmune inflammatory disease affecting both the joints and the skin, with the potential involvement of multiple organ systems. A hallmark feature of PsA is enthesitis—inflammation at the sites where tendons and ligaments insert into bone—which arises from a combination of mechanical stress and immune-mediated inflammation. Another defining characteristic of the disease is the paradoxical coexistence of bone erosion and new bone formation, distinguishing it from other inflammatory arthritides. The therapeutic landscape of PsA has evolved considerably over time. Non-steroidal anti-inflammatory drugs (NSAIDs) remain a cornerstone of symptom management, while conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate, are widely used to control disease progression. The introduction of biologic agents has revolutionized PsA management, with TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors demonstrating efficacy across a broad range of clinical manifestations. More recently, targeted synthetic small molecules—including JAK inhibitors and TYK2 inhibitors—have expanded the armamentarium of available therapies. The overarching goals of treatment in PsA include the suppression of the underlying inflammatory process and the prevention of structural joint damage. The impact of each therapeutic option on cutaneous psoriasis is an additional and important consideration that guides individualized treatment options.

Schlagwörter

Stichwörter der Autor:innen

IL-17 inhibitorsIL-23 inhibitorsJAK inhibitorsTNF inhibitorsTYK2 inhibitorsbiologic agentsoral small moleculespsoriatic arthritisstructural damagetreatment

Autor:innen und Institutionen

  • Department of Rheumatology, St. Paul's Hospital, 55134 Thessaloniki, Greece.
  • Department of Endocrinology, Diabetes and Metabolism, Asclepeion Hospital, Voula, 16673 Athens, Greece.
  • First Propaedeutic Department of Internal Medicine, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
  • Medical School, Reichman University, Herzliya 4610101, Israel.

ORCID-Profile: Ifigenia Kostoglou-Athanassiou, Panagiotis Athanassiou

Zitieren

APA

Athanassiou, L., Kostoglou-Athanassiou, I., Kaiafa, G., Savopoulos, C., Shoenfeld, Y., & Athanassiou, P. (2026). Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies—A Scoping Review. Life, 16(5), 740. https://doi.org/10.3390/life16050740

Vancouver

Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Savopoulos C, Shoenfeld Y, Athanassiou P. Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies—A Scoping Review. Life. 2026;16(5):740. doi:10.3390/life16050740

BibTeX
@article{Athanassiou2026,
  author = {Athanassiou, Lambros and Kostoglou-Athanassiou, Ifigenia and Kaiafa, Georgia and Savopoulos, Christos and Shoenfeld, Yehuda and Athanassiou, Panagiotis},
  title = {Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies—A Scoping Review},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {5},
  pages = {740},
  doi = {10.3390/life16050740}
}
Kostenlos starten →